- Expanding pilelines
- Development of new products in biomaterials, oligonucleotide drugs and celluer medicines
Materiality(material issues)
Mochida Pharmaceutical Group, striving to deliver value as a pharmaceutical company, formulates a basic policy regarding sustainability to contribute to the realization of a sustainable society.
We recognize the issues surrounding sustainability as important management issues and have identified key matters that our group should prioritize in order to enhance sustainable corporate value as material issues.
Identifying Material Issues
Through an assessment focusing on the two aspects, "importance to society" and "importance to the Group," we identified "creation of unique products that meet needs," "stable supply of products with appropriate quality," "maximization of product value," "expansion of human capital" and "thorough compliance" as material issues.
Process of Identifying Material Issues
In 2022, the Group identified material issues through the following process with reference to various principles and guidelines, and we have been working on our initiatives. In May 2025, we plan to review material issues to enhance its alignment with our management plan and set specific KPIs. Moving forward, we will reassess material issues as appropriate in response to changes in society.
[Step1] Identifying issues
Identify a wide range of potential material issues, taking various principles and guidelines such as SDGs, GRI Index and ISO26000, into consideration.
[Step2] Organizing potential material issues
Map the identified issues on two axes: "importance to society" and "importance to the Group" and narrow down the most important matters.
[Step3] Identifying material issues
Identify the Group's material issues through discussions at the meetings of the Board of Directors and the Sustainability Committee.
The Five Material Issues
Among the Group's five material issues, the Group will work on "creation of unique products that meet needs," "stable supply of products with appropriate quality" and "maximization of product value" as material issues in relation to our businesses and on "expansion of human capital" and "thorough compliance" as material issues underpinning the management foundations.
Material issues in relation to our businesses
- We will continue working on the "creation of unique products to meet needs," perceiving increasingly diverse medical and healthcare needs as a business opportunity and adapting to changes of the business environment.
- Through the "stable supply of products with appropriate quality" and "maximization of product value," we will contribute to human health and well-being and seek enhancement in our corporate value.
[Material issues in relation to our businesses]
| Material issues | Vision | Main initiatives | KPI |
FY25‐FY27 MTP(*1) period |
|---|---|---|---|---|
| Creation of unique products that meet needs | Create farsighted and distinctive products to meet diversifying medical and healthcare needs |
|
Number of new drug introductions
|
3 items
|
| Number of healthcare product launches | 2 series | |||
| Number of biomaterial products launches | 5 Products | |||
| Number of clinical trials for oligonucleotide drugs | 1 item | |||
| Number of clinical trials for cellular medicines | 2 items | |||
| Stable supply of products with appropriate quality | Properly implement product quality management and endeavor to maintain a stable supply |
|
Number of significant findings from regulatory inspections | 0 cases |
| Number of products recalls | 0 cases | |||
| Number of outages | 0 cases | |||
| Maximization of product value | Contributing to human health and well-being by maximizing the potential of our products |
|
New drugs: Net sales of 5 major products |
48 billion yen |
| Flagship drug: Volume share of EPA formulations |
No. 1 in Japan | |||
| Flagship drug: Net sales of obstetrics and gynecology field |
15 billion yen | |||
|
Biosimilars: |
3 items |
Material issues underpinning the management foundations
- We believe that a major driver underpinning corporate value creation is "human resources" and therefore, we will strive to create company and workplaces where every employee can demonstrate his or her full potential and grow.
- We are committed to promoting compliance, which is an absolute condition for corporate survival.
[Material issues underpinning the management foundations]
| Material issues | Vision | Main initiatives | KPI |
FY25‐FY27 MTP(*1) period |
|---|---|---|---|---|
| Expansion of human capital | Developing an internal environment where diverse human resources can play an active role and cultivating human resources who will persevere in taking on difficult and new challenges and drive value creation. |
|
Ratio of female managers (Mochida Pharmaceutical) |
12% or more |
| Employee engagement score | (Disclosure of actual values) | |||
| Number of training participants | (Disclosure of actual values) | |||
| Thorough compliance | Seek to increase compliance awareness as an organization |
|
Number of serious non-compliance incidents(*2) | 0 cases |
| Awareness of hotline | 100% |
(*1) MTP : Medium-term Management Plan
(*2)Incidents that have a significant impact on the Group's sales and profits or that are considered necessary to be disclosed outside the company
